TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01516619
Drug: Romiplostim
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Romiplostim will be administered subcutaneously at a dose of 250 μg on the 1st, 3rd and 5th days after the last day of chemotherapy delivery and, then, every two days until the achievement of 75.000 plt/μL.~In the case of unsuccessful use of romiplostim after the second chemotherapy course, dose escalation to 500 μg/day, with the same above-mentioned schedule, will be indicated after the third course and for all the further courses, with a maximum of 8.
Study: NCT00484484
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine
Study: NCT00211224
Drug: Riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04521751
Drug: EMP16-02 120 mg orlistat/40 mg acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
Study: NCT04521751
Drug: EMP16-02 150 mg orlistat/50 mg acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
Study: NCT04398823
Drug: Sclerosing foam of Lauromacrogol
Normalized name: lauromacrogols
DrugBank: Rosin (DB11165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in FS will receive enteroscopy with the sclerosing foam of lauromacrogol.
Study: NCT02985840
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes
Study: NCT02985840
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive intravenous ondansetron(4mg) followed by intravenous dexamethasone (4mg), followed by a single 5ml normal saline flush
Study: NCT00144495
Drug: recombinant human erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks
Study: NCT00144495
Drug: recombinant human erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36000IU(s.c.)/week for 12 weeks
Study: NCT01448707
Drug: Darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
Study: NCT01448707
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
Study: NCT04145700
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab given IV
Study: NCT04145700
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine given IV
Study: NCT04145700
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel given IV
Study: NCT01259089
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01259089
Drug: Hsp90 inhibitor AUY922
Normalized name: Fibrinolysis inhibitor
DrugBank: AUY922 (DB11881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02229851
Drug: somapacitan
Normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
Study: NCT00655811
Drug: Capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application, 0.1%, Capzasin HP; Chattem Inc., Chattanooga, TN, U.S.A
Study: NCT02229851
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
Study: NCT02297100
Drug: Onabotulinumtoxin A
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 100 units of botox spread out among 10 separate injections
Study: NCT00744237
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~* Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~* Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~* Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration
Study: NCT00744237
Drug: Metoprolol ER
Normalized name: Hydrochlorothiazide-Metoprolol ER
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~* Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~* Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~* Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration
Study: NCT00744237
Drug: HCTZ
Normalized name: HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~* HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration
Study: NCT00000206
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04215445
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tab.empagliflozin 25mg once daily for 28 days
Study: NCT01913834
Drug: Forsteo
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous administration 20 micrograms
Study: NCT01913834
Drug: CP046 PTH CriticalSorb
Normalized name: PTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of different doses of drug and nasal delivery devices
Study: NCT02429453
Drug: Four Factor Prothrombin Complex Concentrate
Normalized name: Prothrombin complex concentrate
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S
Study: NCT00541177
Drug: atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% atropine
Study: NCT00541177
Drug: tropicamide
Normalized name: Tropicamide
DrugBank: Tropicamide (DB00809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% tropicamide
Study: NCT00743431
Drug: Caelyx (Pegylated Lyposomal Doxorubicin)
Normalized name: Caelyx
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.
Study: NCT00771693
Drug: Insulin aspart (Novorapid®)
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: a cross-over study with subcutaneous injection of insulin aspart 0.1U/kg, 0.2u/kg or placebo, before the meal, on 3 different occasions.
Study: NCT03780595
Drug: Passiflora incarnata
Normalized name: Passiflora incarnata
DrugBank: Passiflora incarnata flower (DB13974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passiflora pills administration up to 6 pills per day
Study: NCT01506973
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01506973
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01506973
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00613743
Drug: mouth wash with morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine solution 0.2% concentration; 15ml per unit mouthwash 6 time à day
Study: NCT03780595
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control pills administration up to 6 pills per day
Study: NCT03211117
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03460808
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin was used in combination with acetylcysteine and danazol.
Study: NCT03460808
Drug: Acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcysteine was used in combination with atorvastatin and danazol.
Study: NCT03460808
Drug: Danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol was used in combination with atorvastatin and acetylcysteine or as the monotherapy
Study: NCT01840410
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
Study: NCT03652441
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
Study: NCT02130323
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12.5mg (5%) once a week vaginally for 16 weeks
Study: NCT03617900
Drug: Ginger
Normalized name: Ginger
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger extract is contains 100 mg/capsules. Use 2 capsules 3 times/day
Study: NCT03617900
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg paracetamol. use in need
Study: NCT01004250
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
Study: NCT01004250
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
Study: NCT01004250
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
Study: NCT02653014
Drug: KBP-5074
Normalized name: KBP-COVID-19
DrugBank: KBP-COVID-19 (DB15858)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00034788
Drug: Becaplermin
Normalized name: Becaplermin
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00831662
Drug: Diquafosol tetrasodium ophthalmic solution, 2%
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One to two drops in each eye QID for 6 weeks
Study: NCT00318539
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01854294
Drug: GM604
Normalized name: GM604
DrugBank: Alirinetide (DB17007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM604 treated group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
Study: NCT01675453
Drug: 7.2% NaCl plus 6% hydroxyethyl starch 200/0.5
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03472287
Drug: Diacerein 1% Ointment
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein 1% Ointment administered topically
Study: NCT01504477
Drug: Panitumumab and bortezomib
Normalized name: Panitumumab
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.~Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.
Study: NCT00605319
Drug: Toviaz (Fesoterodine)
Normalized name: Toviaz
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4mg to 8mg by mouth once daily
Study: NCT02342314
Drug: LY3143753 (Part A)
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via SC injection
Study: NCT02342314
Drug: LY3185643 (Part B)
Normalized name: SODIUM CHLORITE 0.0256 kg in 1 kg TOPICAL SPRAY [Chlorsan 105 Part B]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered via SC injection
Study: NCT03863015
Drug: Tocilizumab 20 Mg/mL Intravenous Solution
Normalized name: tocilizumab 20 mg/mL intravenous solution
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion
Study: NCT02342314
Drug: rGlucagon (Part B)
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered via SC injection
Study: NCT03312413
Drug: Dexmedetomidine Hydrochloride
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Study: NCT03312413
Drug: Dexmedetomidine Hydrochloride
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine Hydrochloride 0.5 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Study: NCT03312413
Drug: Dexmedetomidine Hydrochloride
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine Hydrochloride 0.7 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Study: NCT01260818
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 g Tranexamic Acid mixed with 100ml saline are kept in wound for 2 hours before drainage is opened postoperatively
Study: NCT00543231
Drug: G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02539459
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg tablets
Study: NCT04176133
Drug: Entolimod
Normalized name: Entolimod
DrugBank: Entolimod (DB12304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
Study: NCT02271360
Drug: Cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
Study: NCT00132275
Drug: Amoxicillin potassium clavulanate
Normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00781105
Drug: Telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg/day, oral tablets, once daily, 52 weeks
Study: NCT00995839
Drug: continuous infusion of terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
Study: NCT00995839
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
Study: NCT00995839
Drug: terlipressin bolus administration
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous terlipressin bolus administration at the dose of 0.5 mg
Study: NCT00443170
Drug: GSK626616, placebo, midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00447564
Drug: Probuphine
Normalized name: Probuphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 implants
Study: NCT03242967
Drug: Vadadustat
Normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral tablet
Study: NCT03242967
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous or intravenous
Study: NCT02145468
Drug: Losmapimod 7.5 mg twice daily
DrugBank: Losmapimod (DB12270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.
Study: NCT00673621
Drug: Salbutamol (Albuterol)
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 puff = 200 mcg total dose
Study: NCT01640639
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide, pill, 50 mg, once p.d., 6 weeks
Study: NCT01609062
Drug: BMN 110
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
Study: NCT01609062
Drug: BMN 110
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
Study: NCT00680992
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
Study: NCT02498912
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine dose 25-30 mg/m2 x 3 days
Study: NCT00316017
Drug: 7.5% hypertonic saline/6% Dextran-70 (HSD)
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 cc dose given as a one-time intravenous (IV) bolus in the pre-hospital setting.
Study: NCT02445053
Drug: ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02789644
Drug: Ursodeoxycholic Acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: Ursodeoxycholic acid 400mg or 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
Study: NCT02834247
Drug: TAK-659
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-659 Tablets.
Study: NCT02834247
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab intravenous infusion.
Study: NCT04152057
Drug: Pyrotinib Maleate Tablets
Normalized name: maleate
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/d,po qd,q3w, 4 cycles
Study: NCT04152057
Drug: Albumin Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125mg/m2,ivggt,d1,q3w,4 cycles.
Study: NCT04152057
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The first week load dose 4mg / kg, followed by 2mg / kg per week, d1,ivggt,q3w,4 cycles.
Study: NCT01468181
Drug: Biguanides (BG)
Normalized name: biguanide
DrugBank: Biguanide (DB13100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.
Study: NCT01314781
Drug: solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: solifenacin 5mg tablet once daily
Study: NCT01683994
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
Study: NCT01468181
Drug: Thiazolidinedione (TZD)
Normalized name: (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
DrugBank: 2,4-thiazolidinedione (DB11898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TZD is a pre-study prescribed dose and is not being provided as part of the trial.
Study: NCT00659555
Drug: pazopanib eye drops
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib will be administered as eye drop solution via topical ocular route. Pazopanib eye drops will be available as white, colorless solution.
Study: NCT00659555
Drug: Ketoconozole tablets
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconozole will be administered as tablets via oral route. Ketoconozole tablets will be present as white, rounded, scored tablets